Clinical Ovarian And Other Gynecologic Cancer Impact Factor


In this retrospective study of 91 patients with recurrent ovarian cancer who received more than 6 infusions of carboplatin between 2005 and 2016, OS was longer by 48 months for those who underwent. Effective Ovarian Cancer Treatment Is Underused, Study FindsEffective Ovarian Cancer Treatment Is Underused, Study Finds. Pages in category "Oncology journals" The following 117 pages are in this category, out of 117 total. Clinical Pathology. An important risk factor is family history of epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, premenopausal breast cancer and/or male breast cancer. Ovarian cancer is the most common cause of cancer death from gynecologic tumors in the United States. Impact Factor of Gynecologic Oncology, 0090-8258, Journal Impact Factor report. Clinical Ovarian Cancer is the world's premier peer-reviewed, tumor-specific, clinical oncology journal devoted to publishing clinically relevant articles on detection, diagnosis, prevention, and. Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML. Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial radiation, endovascular brachytherapy, and systemic brachytherapy in the management of cancer and cardiac and other diseases. Although risk factors often influence the development of cancer, most do not directly cause cancer. In the United States, ovarian cancer is the leading cause of death from gynecologic malignancies with an overall five-year survival rate of <45%. By registering for the conference you grant permission to Conference Series LLC Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. To make an appointment, please call 734-763-6295 (Monday-Friday, 8am-5pm EST). Your doctor can work with you to create a treatment plan. In conclusion, with regard to the treatment of advanced ovarian, fallopian tube, and peritoneum cancer, complete surgery and ≥6 cycles of chemotherapy are independent favorable prognostic factors, and preoperative serum CA125 level of ≤30 U/mL may be a useful predictor of complete surgery in patients treated with NAC. A primary end point of progression-free survival is supported by the Gynecologic Cancer Intergroup, 37 which noted that in trials assessing front-line therapy for advanced ovarian cancer. Check out our highest impact factor journals. Women with a mother, daughter, or sister who has had ovarian cancer are at increased risk. Specific areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers, and prognostic indicators,. In that capacity, I have helped to collect tissue and evaluate the histology of several hundred cases of ovarian cancer. He graduated residency in Obstetrics and Gynecology from Columbia-Presbyterian Medical Center in New York in 1998. Epithelial ovarian cancer accounts for about 70% of all ovarian cancers, making it the most common type. Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Clinical Ovarian and other Gynecologic Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian and other. 3 per 100,000. Browse Gynecologic Oncology. New Clinical Trials Advance Treatment, Diagnosis of Gynecologic Cancers. Peer-Reviewed Publications (Citation source Google Scholar; Impact factor source Specific Journal Website). [1,2] Despite an improvement in surgical technique and development of effective chemotherapy, the overall prognosis of patients with advanced EOC is still poor, with a 5-year survival rate of only 30-40%. Learn more about how to assess your risk, and see Memorial Sloan Kettering's screening recommendations. Five-Year Impact Factor: While the standard Impact Factor measures citations to journal articles published within a 2-year period, the 5-year Impact Factor evaluates citations to journal articles published within a 5-year period to provide a measure of a journal's longer-term influence. each type of cells can develop into different type of tumors Epithelial. Impact Factor:* 2. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test and has been recognized as having the highest impact factor rating of. Journal of Cancer Research & Therapy (JCRT) is an international refereed journal, which publishes high-quality original articles reporting new information on basic and clinical aspects of cancer research and therapy. 198 According to the 2015 Journal Citation Reports® published by Thomson Reuters last month, the Impact Factor of Gynecologic Oncology increased to 4. Cancer of the uterine cervix is the third most common gynecologic cancer diagnosis and cause of death among gynecologic cancers in the United States [1]. The advent of next generation sequencing has led to an era of inexpensive, high throughput DNA sequencing, which is having a major impact on both cancer research and clinical care. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test and has been recognized as having the highest impact factor rating of. Based on our calculation, Genes & Cancer will soon become a very high impact journal. A radiation oncologist specializes in treating cancer with radiation therapy to shrink or destroy cancer cells or to ease cancer-related symptoms. Browse Gynecologic Oncology. A diagnosis of cancer can have a significant impact on family and friends. Learn about clinical trials. The role of germline mutations in BRCA1 and BRCA2 genes in the risk of the development of ovarian cancer is clinically well established. Several adjuvant therapies are used depending on grade and stage of the tumor and other patient-related factors. 1,2 In the United States alone, it accounted for an estimated 22,240 new cases and 14,070 deaths in 2018. Introduction. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. (NIH) and its National Cancer Institute (NCI) are doing in the fight against cancer. Saketh Guntupalli said his patient Peyton Linafelter had one of the worst cases of cancer that he has ever seen. Ovarian cancer is the 7th most common malignancy in British Columbia women with a crude incidence rate of 17. Gynecologic Oncology has an Impact Factor of 3. In conclusion, with regard to the treatment of advanced ovarian, fallopian tube, and peritoneum cancer, complete surgery and ≥6 cycles of chemotherapy are independent favorable prognostic factors, and preoperative serum CA125 level of ≤30 U/mL may be a useful predictor of complete surgery in patients treated with NAC. Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma. Meet Frank Loula, an inspirational James volunteer Home > Cancer Specialties > Clinical Trials > Find a Clinical Trial > Phase I Active Immunotherapy Trial With A. Get the latest Gynecology & Obstetrics news, medical journals & clinical articles published daily by physician editors. The other 2 major categories of invasive […]. It ranks fourth in cancer deaths among women and causes more deaths than any other cancer of the female reproductive system. Dissemination of ovarian cancer cells throughout the abdominal cavity remains the major clinical challenge in advanced ovarian cancer. Histologically-confirmed recurrent ovarian, fallopian tube, primary peritoneal cancer, endometrial, vaginal, or cervical cancer in the abdomen and pelvis Subjects with stage IV disease are eligible as long as disease elsewhere (other than the site(s) to receive radiation therapy [RT]) is undetectable or stable (>/+3 months) and immediate. Forestry Commission Clinical Ovarian and other Gynecologic Cancer Kadmoniyot Gender and History International Journal of Tuberculosis and Lung Disease. , underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research. Ovarian cancer is the growth of abnormal malignant cells that begins in the ovaries (women’s reproductive glands that produce eggs) or in the fallopian tubes. The journal Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology, is pleased to announce the launch of a special issue on gynecologic cancer prevention, treatment and survivorship in obese women. Memoir of a Debulked Woman is an important, well argued, and exhaustively researched book. While other anti-angiogenics have been studied, none to date have demonstrated the overall treatment effect of Avastin in ovarian cancer. Elena , Paige A. Clear-cell carcinoma, mucinous carcinoma and endometrioid carcinoma each make up 6 to 10 percent of ovarian cancers. identify five prognostic subtypes using 16 key molecular features and propose a decision tree based on six clinically assessable features that classifies patients into the subtypes. Each issue of Cancer Forum features: an in-depth forum on key aspects of cancer treatment and control; articles, research reports and cancer news; reviews of the latest cancer publications. Learn about clinical trials. Gynecologic cancers arising from the female reproductive system include ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer and vulva cancer. The loss of ovarian function during the menopause transition coincides with weight gain, increases in abdominal adiposity, and impaired metabolic health. Journal of Cancer Survivorship publishes original research on humans (both laboratory and clinical), systematic and meta-analytic literature reviews, clinical investigations and policy-related research that can impact the quality of care and quality of life of adult cancer survivors. Diagnosis of disease based on the laboratory analysis of bodily fluids, such as blood, urine, and tissue homogenates or extracts using the tools of chemistry, microbiology, hematology and molecular pathology is known as clinical pathology. Clinical Ovarian Cancer is the world's premier peer-reviewed, tumor-specific, clinical oncology journal devoted to publishing clinically relevant articles on detection, diagnosis, prevention, and. Cancer Journals | CancerIndex. Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc. Clinical Ovarian and other Gynecologic Cancer Journal of the Japanese and International Economies Expert Opinion on Investigational Drugs Nordic Theatre Studies Soviet studies in history Journal of the Institution of Engineers (India): Civil Engineering Division Mana: Estudos de Antropologia Social. Introduction. Because of the complexities of ovarian cancer, it is imperative that your treatment is conducted at a cancer center with an experienced team. 3 per 100,000. About 5 to 10 percent of ovarian cancers are familial, and several familia. HBOC is characterized by a high risk of breast and ovarian cancers, and an increased risk of other cancers such as male breast cancer, prostate, pancreatic, and melanoma. Material And Methods: Fifty-eight CART procedures were performed in nine patients with ovarian, endometrial, or cervical cancer from February 2013 to September 2014. New Clinical Trials Advance Treatment, Diagnosis of Gynecologic Cancers. Clinical Ovarian and other Gynecologic Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian and other. Staging and initial surgical management should be performed by a gynecologic oncologist whenever possible. each type of cells can develop into different type of tumors Epithelial. The impact of post-progression therapy on clinical trial endpoints. In contrast, another interpersonal factor, trust in physicians, was not associated with prolonged symptom duration. The choice of which blood tests to do depends on the type of cancer a woman has. Serum protein markers for early detection on ovarian cancer. Polygenic risk scores for breast and ovarian cancer Whole-Genome and Whole-Exome Sequencing Polymorphisms underlying polygenic susceptibility to breast and gynecologic cancers are considered low penetrance , a term often applied to sequence variants associated with a minimal to moderate risk. As of 2012 continued as Clinical Ovarian and Other Gynecologic Cancer. I am the pathologist for the ovarian cancer section of the "Nurses' Health Study," an epidemiology based investigation of risk factors for disease in women sponsored by NIH. They can occur during the childbearing years or after menopause. The risk of epithelial ovarian cancer increases with age, especially after the age of 50. Journal of Cancer is a peer-reviewed journal publishing papers of high quality in all areas of cancer related fields, especially novel concepts, new methods. Sex-based co. View More ». Despite recent promising advances in cancer research, there are still surprising gaps in the fundamental knowledge about ovarian cancer. Limitations in our understanding about the biology of the disease—and gaps in the evidence base to support diagnosis, delivery of care, and survivorship—impede efforts to improve the prevention, early detection, treatment, and ongoing care for women with. Working on the special issue, Guest Editors Dr Susan C. A risk factor is anything that increases a person’s chance of developing cancer. Ovarian cancer probably represents the best example of how a well-prepared specialist can positively modify the clinical and oncologic outcomes of women. Several adjuvant therapies are used depending on grade and stage of the tumor and other patient-related factors. Hereditary colon cancer. An integrated physico-chemical approach for explaining the differential impact of FLASH versus conventional dose rate irradiation on cancer and normal tissue responses. The Annual Report. Ovarian cancer is the fifth most common cause of cancer deaths in women, with more than 22,000 diagnoses and around 14,000 deaths each year. Fox, MD, explains how collaboration between payers and gynecologic oncologists, as well as other specialists, can be valuable in improving the management of ovarian cancer. The journal's publications cover all imaging modalities, radiology issues related to patients, policy and practice improvements, and clinically-oriented imaging. If it is diagnosed in the early stages, there is a 94 percent chance of surviving for at least 5 more years. Journal of Cancer Science and Clinical Therapeutics is an open access, peer reviewed journal publishes articles related to the ever expanding research on Cancer. The Foundation for Women's Cancer (FWC) steadily pursues its mission of supporting research, education and public awareness of gynecologic cancers. Federal Government. Ovarian cancer is the leading cause of gynecologic cancer deaths among American women. Proteomics and Biomarkers for Ovarian Cancer Diagnosis Annals of Clinical & Laboratory Science. In studies examining the effects of beta blockers on survival in patients with breast, lung, ovarian cancer or melanoma, patients were taking beta blockers for cardiac or other clinical indications and not for cancer therapy 5-7,11,13,15. In this study, we have examined a younger (≤ 40 years of age) subpopulation of these women with high grade/ high stage gynecologic malignancies, attempting to identify unique genetic abnormalities or combinations thereof through tissue block specimens. With a particular focus on breast and ovarian cancers, Dr. About the journal. 442, and 34. In fact, we are one of the few cancer centers in the nation to house a prestigious federally funded ovarian SPORE (Specialized Program of Research Excellence) program. Patients with a diagnosis or strong suspicion of cancer are given appointments within 72 hours. It ranks fourth in cancer deaths among women and causes more deaths than any other cancer of the female reproductive system. Although risk factors often influence the development of cancer, most do not directly cause cancer. Australia has the highest incidence of skin cancer in the world, exceeding 2000 per 100 000 person-years and it is increasing [1]. They can occur during the childbearing years or after menopause. An integrated physico-chemical approach for explaining the differential impact of FLASH versus conventional dose rate irradiation on cancer and normal tissue responses. Material And Methods: Fifty-eight CART procedures were performed in nine patients with ovarian, endometrial, or cervical cancer from February 2013 to September 2014. Too much CA-125 in your blood can be a sign of ovarian cancer. Impact Factor of Gynecologic Oncology, 0090-8258, Journal Impact Factor report. We organise Oncology & Cancer meetings in the fields related to Oncology and Cancer like Haematology, Radiology, Biomarkers and Gynaecologic. It is fairly rare in the United States. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are. They took a. Cancer Forum Published March, July, and November from 2000 - 2017 , Cancer Forum is a journal for multidisciplinary health professionals working in cancer. Primary cytoreductive surgery (PDS) followed by adjuvant chemotherapy has historically been the standard of care for women with advanced ovarian. Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Optimum care of female transplant recipients requires gynecologic care at several stages through the allogeneic hematopoietic stem cell transplantation (HCT) process. Although risk factors often influence the development of cancer, most do not directly cause cancer. It covers research on the detection, diagnosis, prevention, and treatment of ovarian cancer. Genes & Cancer is a member of the Committee on Publication Ethics (COPE) and other international committees. This work has been complemented by clinical studies, establishing the prognostic significance of c-Met in tissue samples of breast cancer. Contributions include original clinical studies, review articles, and experimental investigations with clear clinical relevance. An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies of Cancer Survivors Jessica L. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators. Hereditary colon cancer. Publications evaluating only nonepithelial ovarian cancer were excluded from the analysis. Ovarian cancer rarely causes symptoms early on, and as a result, many people aren't diagnosed until its later stages, when it becomes difficult to treat. Ovarian cancer is uniquely positioned to take advantage of “weaponized” sex determining growth factors in the treatment of cancer. and clinical trials in ovarian and breast cancer as of February 2016, Total Impact Factor= 374,4 Scientific Affiliations Italian Association Medical Oncology (AIOM) American Society Clinical Oncology (ASCO) International Gynecologic Cancer Society Editorial Board Cancer Chemotherapy Pharmacology Tumori. As of 2012 continued as Clinical Ovarian and Other Gynecologic Cancer. Annals of Medical and Clinical Oncology is a peer-reviewed journal dedicated towards cancer research. Ovarian Cancer cautioning signs incorporate progressing torment or issues in the gut or back, anomalous vaginal dying, sickness, and bloating. Michael Shepard discusses development of trastuzumab, the first fully humanized monoclonal antibody for solid tumor treatment and the first tyrosine kinase inhibitor, for treatment of breast cancer. Journal of Cancer Science and Clinical Therapeutics is an open access, peer reviewed journal publishes articles related to the ever expanding research on Cancer. Epithelial ovarian cancer (EOC) accounts for 3% of all cancers among women world-wide (2. Optimal surgical cytoreduction is associated with improved survival [1]. She is also the co-chair for the CSSRC. The Road Ahead for Ovarian Cancer Opening the 20 th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M. Clinical research is a critical component in expanding treatment options for people with all types of cancer. ovarian cancer, tumor diameter≥10 cm, and a history of VTE, with the risk ratios being 20. Ovarian Cancer Facts and Statistics. The journal focuses on experimental oncology, clinical oncology and cancer epidemiology and its prevention. Each issue of Cancer Forum features: an in-depth forum on key aspects of cancer treatment and control; articles, research reports and cancer news; reviews of the latest cancer publications. National clinical trial collaborators; Get answers to FAQs; Take the clinical trials IQ quiz; PRE-ACT; Meet trial participants; Contact clinical research personnel; Commission on Cancer accreditation; Find a doctor; Life and Love After Cancer; Patient resources. An estimated 22,440 American women will be diagnosed with ovarian cancer in 2017, according to the American Cancer Society, and about 14,080 will die of the disease. The Annals of Gynecologic cancer covers all latest research studies and developments in this field and reaches out to the right target audience. Doubilet, Steven R. Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer. Alvarez has served on study sections for the NCI Clinical Oncology Section and the Department of Defense’s Ovarian Cancer Research Program. Genetics of Breast and Gynecologic Cancers (PDQ®)-Health Professional Version - National Cancer Institute Genetics of Breast and Gynecologic Cancers (PDQ®)-Health Professional Version Penetrance of Inherited Susceptibility to Hereditary Breast and/or Gynecologic Cancers. The findings by academics at The University of Manchester, published in the Journal of Obstetric, Gynecologic and Neonatal Nursing, compared Johnson's Baby Top-to-Toe wash against plain bath water. Patients with a diagnosis or strong suspicion of cancer are given appointments within 72 hours. 1 As a result, there is a pressing need to determine appropriate measures of ovarian cancer care quality. Researchers are constantly looking for clues such as lifestyle, diet, and medicines that may alter the risk of ovarian cancer. Gynecology journal, Clinical Obstetrics and Reproductive Medicine provides all obstetricians, gynaecologists and specialists in reproductive medicine with comprehensive resource and ready access to up-to-date information on all aspects of obstetrics and gynaecology. Download with Google Download with Facebook. 56]) and clear cell (10. Hypodontia might serve as a risk factor for EOC detection. Gynecologic oncology at Massey. Gynecologic oncologists have an essential role to treat women with gynecological cancer. 929, ranking it in the top 10% of journals in the Obstetrics and Gynecologic category of the Journal Citation Reports and in the top 30% in the. While the clinical trials of anti-c-Met therapy in advanced breast cancer progress, there is a need to review the existing evidence so that the potential of these treatments can be better appreciated. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across. Other studies are testing new drugs for ovarian cancer risk reduction. Family history is the strongest risk factor for ovarian cancer. Cancer immunotherapy is a form of cancer treatment that uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Top Journals in other. The loss of ovarian function during the menopause transition coincides with weight gain, increases in abdominal adiposity, and impaired metabolic health. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer. For epithelial ovarian cancer, CA-125 is the tumor marker used most often to check for recurrence. Read the latest articles of Clinical Ovarian and Other Gynecologic Cancer at ScienceDirect. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN),. We have used a two-step strategy to identify plasma proteins that could be use. Discover the promise of cancer immunotherapy: learn more about this revolutionary cancer treatment and its potential to treat and cure all types of cancer. A clinical study of ovarian cancer was conducted at the Gynecologic Oncology Unit at University of Turin (Turin, Italy) between October 1991 and February 2000. If it is diagnosed in the early stages, there is a 94 percent chance of surviving for at least 5 more years. Use of talcum powder. As leading causes of death that endanger women's reproductive health, uterine cancer, ovarian cancer, and cervical cancer are characterized by high degree of malignancy, metastasis, and recurrence. The Journal, which presents research, clinical opinions and case reports from the brightest minds in gynecologic surgery. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors - Gynecologic. This type of ovarian cancer is divided into serous, mucinous, endometrioid, clear cell, transitional and undifferentiated types. Due to the advanced stage (stage IV) of her ovarian cancer, as well as her unusually young age for the diagnosis, he has referred to Linafelter as a medical mystery. Impact Factor:* 1. Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Other factors – your risk may be higher if you have a history of a condition called endometriosis. Among the top ovarian cancer researchers in the country, Penn Medicine Gynecologic Pathologist Ronny Drapkin, MD, PhD, is a passionate advocate of pioneering scientific research to detect and treat ovarian cancer. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) Young et al. Cancer Research and Resource Centers. It is the ninth most common cancer in women. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test and has been recognized as having the highest impact factor rating of. At the time of diagnosis and first treatment, ovarian cancers are assigned to a stage based upon tumor size, the involvement of lymph nodes and the spread to body parts beyond the lymph nodes. Epithelial ovarian carcinoma (EOC) is the most lethal gynecologic malignancy. What is cancer research? Cancer research, or clinical trials, are studies that involve people and test new ways to prevent, detect, diagnose, or treat cancer and other diseases. Lung cancer signatures in plasma have been studied both in mouse models and in human with data implying concordance between findings in both species [42]. August 30, 2019 [ MEDLINE Abstract] Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. Clinical Ovarian and other Gynecologic Cancer. The clinical trials conducted at DF/BWCC have had a meaningful impact on the type of care administered worldwide. Cancer Causes Control. Remedy Publications has launched this journal to make it an Open Platform for gynecologists and Obstetricians read, share, and publish most recent updates in this field of research. She is also the co-chair for the CSSRC. We aimed to elucidate the involvement of miR-124 and SphK1 in migration and invasion of ovarian cancer. Ovarian cancer is the most lethal gynecologic cancer. She is responsible for teaching the fellows and is involved in running the fellows. Winter WE 3rd, Maxwell GL, Tian C, et al. Germ cell ovarian cancer: Germ cell tumors account for about 5% of ovarian cancers. The journal's publications cover all imaging modalities, radiology issues related to patients, policy and practice improvements, and clinically-oriented imaging. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across. ISSN: 0378-7346. Recognizing the risk factors can help women take advantage of available health screenings that can detect problems before they become serious. Clinical research is a critical component in expanding treatment options for people with all types of cancer. An ethics review committee at the university approved the study and all participants provided informed consent. Treatment for ovarian cancer usually involves a combination of surgery and chemotherapy. 5 to 4:1 [ 8 - 12, 14, 16, 17, 33, 34 ]. However, with the mounting evidence of the potential impact of beta blockers on cancer outcomes, a. CRJ seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. Goldstein, Ulrike M. Ovarian cancer is the most aggressive gynecological cancer with a 5-year overall survival of 40%. Gynecologic cancers impact women of every age—it's time to start a conversation about these life-threatening cancers and their symptoms. We first divide the patients. Follow-up for ovarian cancer usually includes blood tests for tumor markers or hormones that help recognize recurrence. National clinical trial collaborators; Get answers to FAQs; Take the clinical trials IQ quiz; PRE-ACT; Meet trial participants; Contact clinical research personnel; Commission on Cancer accreditation; Find a doctor; Life and Love After Cancer; Patient resources. Optimal surgical cytoreduction is associated with improved survival [1]. RRBSO has an important impact on breast cancer risk in this population; the 50 % reduction in breast cancer incidence associated with premenopausal RRBSO in high-risk women would also need to be considered in these prospective studies before changing clinical practice for ovarian cancer prevention among BRCA1/2 mutation carriers. The choice of which blood tests to do depends on the type of cancer a woman has. Five-Year Impact Factor: While the standard Impact Factor measures citations to journal articles published within a 2-year period, the 5-year Impact Factor evaluates citations to journal articles published within a 5-year period to provide a measure of a journal's longer-term influence. Impact Journals, LLC meets the Wellcome Trust Publisher Requirements,. An ovarian cyst is a sac or pouch filled with fluid or other tissue that forms in or on an ovary. Hormone imbalances are common risk factors for cancers, but your doctor can help you and your hormones find a healthy balance. Top Journals in other. Genetics of Breast and Gynecologic Cancers (PDQ®)-Health Professional Version - National Cancer Institute Genetics of Breast and Gynecologic Cancers (PDQ®)-Health Professional Version Penetrance of Inherited Susceptibility to Hereditary Breast and/or Gynecologic Cancers. More than any other field in obstetrics and gynecology, gynecologic oncology has seen an explos. The incidence rate has remained relatively stable over the past 30 years with a 5-year relative survival of about 35%. Cancer is not one disease. Cervical cancer is the only gynecologic cancer that can be prevented with routine screening. Material And Methods: Fifty-eight CART procedures were performed in nine patients with ovarian, endometrial, or cervical cancer from February 2013 to September 2014. Deborah Levine, Douglas L. Additionally, an estimated 25,580 new cases will be diagnosed, approximately 60% to 70% of which will be diagnosed at an advanced stage because of the lack of effective screening and early warning signs (1, 2). A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease. While significant advances have been made in surgical and chemo-based treatments for ovarian cancer, the survival rates have only modestly improved. identify five prognostic subtypes using 16 key molecular features and propose a decision tree based on six clinically assessable features that classifies patients into the subtypes. Please visit the BMC website for a complete list of all of our journals. Other risk factors that can contribute to a greater risk of sexual problems in men are cigarette smoking, history of heart disease, high blood pressure, and diabetes. Impact Factor of Gynecologic Oncology, 0090-8258, Journal Impact Factor report. 1 For early. Data are presented to assist in deciding what operation should be performed and when it should occur. Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version - National Cancer Institute Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version Penetrance of Inherited Susceptibility to Hereditary Breast and/or Gynecologic Cancers. In this retrospective study of 91 patients with recurrent ovarian cancer who received more than 6 infusions of carboplatin between 2005 and 2016, OS was longer by 48 months for those who underwent. Other studies are testing new drugs for ovarian cancer risk reduction. 5 to 4:1 [ 8 - 12, 14, 16, 17, 33, 34 ]. Ovarian Cancer Risk Factors. Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Sensitivity across all types of ovarian cancers was 96% when OVA1 was added to routine clinical assessment, and this result was nearly identical to the first pivotal study. Epithelial ovarian carcinoma (EOC) is the most lethal gynecologic malignancy. Treatment of recurrent ovarian cancer remains a challenge despite advances in surgical and chemotherapeutic. The risk of breast and ovarian cancer among women with mutations such as BRCA1 and BRCA2 mutations can be mitigated by operations to remove the organs at greatest risk. Gynecologic cancers and their treatments can profoundly impact sexual identity, sexual functioning, and the sexual relationship of cancer survivors. Clinical research is a critical component in expanding treatment options for people with all types of cancer. The forthcoming Special Issue focuses on the "Diagnosis and Treatment for Gynecologic Cancers" and calls for papers on a wide range of. Clinical Ovarian Cancer is the world's premier peer-reviewed, tumor-specific, clinical oncology journal devoted to publishing clinically relevant articles on detection, diagnosis, prevention, and. Hormone imbalances are common risk factors for cancers, but your doctor can help you and your hormones find a healthy balance. Ovarian Cancer. They can occur during the childbearing years or after menopause. Importantly, within the test group OVA1 identified 83% of cancers missed by clinical assessment and 71% of cancers missed by CA125. Journal of Obstetrics and Gynecology is the best among the high Impact Factor Journals in Obstetrics and Gynecology. 19, MNiSW – 40 Average rejection rate – 84. The Journal is concerned with basic, translational and clinical research, across different disciplines and areas, enhancing insight in understanding, prevention, diagnosis and treatment of cancer. The impact of post-progression therapy on clinical trial endpoints. Ovarian cancer is the fifth leading cause of cancer-related death among women in the United States and accounts for more deaths than all other gynecologic cancers combined. Read the latest articles of Clinical Ovarian Cancer at ScienceDirect. Ovarian, fallopian tube, and primary peritoneal cancer screening is not currently recommended as part of routine cancer screening. Clinical Genitourinary Cancer, British Medical Journal, Urologia Internationalis, American Journal of Surgery, Urologic Clinics of North America, Urologic Radiology, International Urogynecology Journal, LUTS: Lower Urinary Tract Symptoms, European Journal of Clinical Microbiology & Infectious Diseases. Investigations relating. A comprehensive listing of over 250 oncology and related journals. Lung cancer signatures in plasma have been studied both in mouse models and in human with data implying concordance between findings in both species [42]. different types of gynecologic cancer. She is also the co-chair for the CSSRC. | N Engl J Med 2018; 379:1955-1957 Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer-related death in women worldwide. Gynecologic and Obstetric Investigation Impact Factor, IF, number of article, detailed information and journal factor. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. Gynecologic cancer disparities in the United States refer to differences in incidence, prevalence, and mortality from gynecologic cancers between population groups. The Annals of Gynecologic cancer covers all latest research studies and developments in this field and reaches out to the right target audience. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, et al. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are. Over 500,000 women worldwide are diagnosed with ovarian or endometrial cancer each year. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN),. We aimed to elucidate the involvement of miR-124 and SphK1 in migration and invasion of ovarian cancer. Clinical Ovarian and other Gynecologic Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian and other. Objective Physical activity plays a key role in cancer survivorship. : Stages III and IV serum ovarian cancer are the most lethal of all gynecologic cancers; however, some advanced-stage ovarian cancer patients are long-term survivors. The AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. The OCRP is the leading funder of new ovarian cancer research projects and the second-leading funder overall of ovarian cancer. Gynecologic oncologists can perform surgery on and give chemotherapy (medicine) to women with ovarian cancer. Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. 56]) and clear cell (10. Surgery is the most important treatment to offer possibility of cure or prolong survival. Clinical Ovarian Cancer & Other Gynecologic Malignancies;. However, the undelying mechanisms are poorly defined, so that effective pharmacologic targets are still missing. Cancer Research Journal (CRJ) publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention and epidemiological research. An ovarian cyst is a sac or pouch filled with fluid or other tissue that forms in or on an ovary. However, with the mounting evidence of the potential impact of beta blockers on cancer outcomes, a. The four subtypes of epithelial ovarian cancer are serous, mucinous, clear cell, and endometrioid, with serous being the most common variety. You may wish to submit to another BMC journal. Brown, Rochelle F. Ronny Drapkin, Gynecologic Pathologist. Fotopoulou et al. Browse Gynecologic Oncology. Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Gynecologic cancer disparities in the United States refer to differences in incidence, prevalence, and mortality from gynecologic cancers between population groups. Archives of Clinical and Medical case reports covers the major topics like case reports in Internal Medicine, Hepatology, Microbiology, Toxicology, Molecular Biology, Neuroscience, Obstetrics and Gynecology, Physical Medicine, Surgical Oncology, Family Medicine, Cancer case reports, Pulmonology and other surgery reports. I am the pathologist for the ovarian cancer section of the "Nurses' Health Study," an epidemiology based investigation of risk factors for disease in women sponsored by NIH. Due to the relatively asymptomatic nature and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic malignancy. Ovarian cysts are very common. Diabetes, obesity, hyperlipidemia, Polycystic Ovarian Syndrome, bone disease, and various other disorders can interrupt this growth and produce long-term health concerns for the child. Methods: We propose an effective ensemble feature learning method to identify the risk factors for predicting secondary cancer by considering class imbalance and patient heterogeneity. She is responsible for teaching the fellows and is involved in running the fellows. Ovarian Cancer High Impact Factor Journals Ovarian cancer is the 5th most cancer among all the cancers in women but compare to all, the ovarian cancer is the dangerous it leads to death. Cancer immunotherapy is a form of cancer treatment that uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Hence, diagnosing at early stage is crucial to improve the prognosis of ovarian cancer. As leading causes of death that endanger women's reproductive health, uterine cancer, ovarian cancer, and cervical cancer are characterized by high degree of malignancy, metastasis, and recurrence. In 2017, 22440 new cases and 14080 deaths were expected, making ovarian cancer the fourth most common cause of cancer-related deaths in females. Contingent upon the malignancy stage, ovarian tumor treatment incorporates surgery and chemotherapy. Among women with endometriosis, we also examined the effect of other treatments on ovarian cancer risk.